Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Debra J Zack

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Arthritis and Rheumatism|May 10, 2005
Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis modelsGeorg Schett, Scot Middleton, Brad Bolon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responsesMarina Stolina, Denise Dwyer, Michael S Ominsky, et al.
Molecular Immunology|March 6, 2003
Cell type specific targeted intracellular delivery into muscle of a monoclonal antibody that binds myosin IIbRichard H Weisbart, Fusheng Yang, Grace Chan, et al.
Arthritis Research & Therapy|August 2, 2011
A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the kneeStanley B Cohen, Susanna Proudman, Alan J Kivitz, et al.
Arthritis Research & Therapy|October 19, 2010
A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritisMario H Cardiel, Paul P Tak, William Bensen, et al.
Clinical and Experimental Rheumatology|February 14, 2012
A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune diseaseHailing Hsu, Sanjay D Khare, Frances Lee, et al.
The Lancet. Rheumatology|January 22, 2024
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trialCory A Perugino, Zachary S Wallace, Debra J Zack, et al.
Arthritis Research & Therapy|August 21, 2015
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trialsWilliam Stohl, Joan T Merrill, R John Looney, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 17, 2023
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 TrialJoan T Merrill, Joel Guthridge, Miles Smith, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Arthritis and Rheumatism|May 10, 2005
Additive bone-protective effects of anabolic treatment when used in conjunction with RANKL and tumor necrosis factor inhibition in two rat arthritis modelsGeorg Schett, Scot Middleton, Brad Bolon, et al.
Journal of Immunology (Baltimore, Md. : 1950)|November 21, 2007
Continuous RANKL inhibition in osteoprotegerin transgenic mice and rats suppresses bone resorption without impairing lymphorganogenesis or functional immune responsesMarina Stolina, Denise Dwyer, Michael S Ominsky, et al.
Molecular Immunology|March 6, 2003
Cell type specific targeted intracellular delivery into muscle of a monoclonal antibody that binds myosin IIbRichard H Weisbart, Fusheng Yang, Grace Chan, et al.
Arthritis Research & Therapy|August 2, 2011
A randomized, double-blind study of AMG 108 (a fully human monoclonal antibody to IL-1R1) in patients with osteoarthritis of the kneeStanley B Cohen, Susanna Proudman, Alan J Kivitz, et al.
Arthritis Research & Therapy|October 19, 2010
A phase 2 randomized, double-blind study of AMG 108, a fully human monoclonal antibody to IL-1R, in patients with rheumatoid arthritisMario H Cardiel, Paul P Tak, William Bensen, et al.
Clinical and Experimental Rheumatology|February 14, 2012
A novel modality of BAFF-specific inhibitor AMG623 peptibody reduces B-cell number and improves outcomes in murine models of autoimmune diseaseHailing Hsu, Sanjay D Khare, Frances Lee, et al.
The Lancet. Rheumatology|January 22, 2024
Evaluation of the safety, efficacy, and mechanism of action of obexelimab for the treatment of patients with IgG4-related disease: an open-label, single-arm, single centre, phase 2 pilot trialCory A Perugino, Zachary S Wallace, Debra J Zack, et al.
Arthritis Research & Therapy|August 21, 2015
Treatment of systemic lupus erythematosus patients with the BAFF antagonist "peptibody" blisibimod (AMG 623/A-623): results from randomized, double-blind phase 1a and phase 1b trialsWilliam Stohl, Joan T Merrill, R John Looney, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|July 17, 2023
Obexelimab in Systemic Lupus Erythematosus With Exploration of Response Based on Gene Pathway Co-Expression Patterns: A Double-Blind, Randomized, Placebo-Controlled, Phase 2 TrialJoan T Merrill, Joel Guthridge, Miles Smith, et al.
Pageof 2